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Abstract 
Background: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and 
platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for 
recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) 
demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA 
mutant patients. 
Objectives: To highlight the mechanism of action, pharmacokinetics, clinical activity, indications 
and current strategies of development of Olaparib, Niraparib, Rucaparib, Talazoparib and Veliparib, 
the 5 most relevant PARPis. 
Methods: We performed a review on Pubmed using 'ovarian cancer' and the name of each PARPi 
(PARP inhibitor) discussed in the review as Medical Subject Headings (MeSH) keywords. The 
same search was performed on “clinicaltrial.gov” to identify ongoing clinical trials and on 
“google.com/patents” and “uspto.gov” for recent patents exploring PARPIs in ovarian cancer.  
Results: Olaparib, Niraparib and Rucaparib are already approved for treatment of recurrent EOC 
and their indications are partially overlapping. Talazoparib and Veliparib are promising PARPis, 
but currently under investigation in early phase trials. Several studies are evaluating PARPis in 
monotherapy or in associations, in a wide range of settings (i.e. first line, neoadjuvant, platinum-
sensitive and resistant disease). 
Conclusion: PARPis are valuable options in patients with recurrent ovarian cancer with promising 
activity in different stages of this disease. Further studies are required to better define optimal 
clinical settings, predictors of response beyond BRCA mutations and strategies to overcome 
secondary resistance of PARPis therapy in EOC. 
Keywords: ovarian cancer, PARP inhibitors, olaparib, niraparib, rucaparib, veliparib, talazoparib, 
recent patents. 
 
 
 
 
 
 
 
 
 
  
1. INTRODUCTION 
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy with 22440 estimated 
new cases and 14080 deaths in the United States in 2017 [1]. It is frequently diagnosed at advanced 
stage and standard therapeutic strategy consists of optimal debulking surgery (absence of residual 
disease) and platinum-based chemotherapy [2]. However, despite optimal surgery, about 70% of 
patients experience relapse [3]. Probability of response and prognosis of relapsed patients is related 
to progression/relapse free interval from last platinum therapy (Platinum free interval, PFI). Patients 
with platinum-refractory (PFI within 4 weeks) and platinum resistant (PFI within 6 months) disease 
would receive a single-agent chemotherapy (above all Pegylated Liposomal Doxorubicin-PLD, 
Taxanes, Gemcitabine, Etoposide or Topotecan) with low response rate and poor prognosis. On the 
other hand, patients that are platinum partially-sensitive (PFI between 6 and 12 months) and 
platinum sensitive (PFI longer than 12 months) could receive a platinum based therapy with a better 
prognosis and longer survival [2]. In this landscape, characterized by few therapeutic options and a 
narrow range of drugs that improve survival, inhibitors of poly (ADP-ribose) polymerases (PARPis) 
emerged as an exciting option [4]. Olaparib, Rucaparib, Niraparib, Veliparib and Talazoparib are 
the most studied PARPis and the first three have already been approved in different setting of 
relapsed EOC, determining a radical change in current practice.  
 
1.1. DNA repair and Homologous Recombination Deficiency 
DNA damage is a frequent event during cell life; it can be spontaneous (e.g. replication error) or 
caused by cell metabolism or by environmental agents[5]. It can result in single strand DNA breaks 
(SSBs) or double strand DNA breaks (DSBs) that cause loss of genome integrity and cell death, if 
not correctly repaired [6]. There are six main DNA repair pathways [7] [8]. Mismatch Repair 
(MMR), Nucleotide Excision Repair (NER), Base Excision Repair (BER), Trans-lesional Synthesis, 
Non Homologous end joining (NHEJ), and Homologous recombination (HR) [9]. The last two 
pathways are responsible for repairing DSBs; HR is a high fidelity repair mechanism, active during 
Phase G2-S of cell cycle[10, 11], whereas NHEJ is faster but error prone [12] [13]. If HR pathway 
is altered, leading to Homologous Recombination Deficiency (HRD), cells rely above all on NHEJ 
[14], with a less preserved genomic integrity and a higher risk to develop cancers [12] [13]. The 
first HR proteins that have been studied were Breast Related Cancer Antigen (BRCA) 1[15] [16] 
and 2 [17], whose germline mutations and, consequently, loss of function were correlated with an 
increased risk of breast cancer (ranging from 57% in BRCA1 mutation to 45% in BRCA2 mutation) 
and ovarian cancer (ranging from 11% in BRCA 1 mutation to 40 % in BRCA2 mutation) [18] [19].  
BRCA mutated OC display distinctive biological and clinical features[20], being usually high grade 
cancers (G2-G3), with serous or undifferentiated histology [21]. Moreover, they are frequently 
diagnosed at an advanced stage [22] and in young women but BRCA mutated patients have a better 
prognosis in comparison with BRCA wild type (BRCA WT) EOC.  [21] [23] [24]. Until recent 
approval of the new drugs, PARPis, patients with gBRCAm EOC had the same treatment of BRCA 
wild type EOC [25] [26] [27] . Recently TCGA demonstrated that almost half of high grade serous 
ovarian cancer (HGSOC), the most frequent EOC histology, exhibits HRD [28]. Germline BRCA1 
and 2 [22] [29] account for 22.6% of mutations in HGSOC, usually accompanied by loss of 
heterozygosis (LOH), while somatic mutations are present in 6-7% [30] and BRCA1 
hypermethylation is found in about 10% of HGSOC [28]  Other altered genes in HRD pattern are 
EMSY (8%), PTEN (Phosphatase and Tensin Homolog) (7%), RAD 51C (3%), ATM/ATR 
(Ataxia-telangiectasia mutated and ATM- and RAD3-related) (2%), Fanconi Anemia genes (5%) 
and RAD 50 (<1 %) [28]. Sporadic EOCs that exhibit HRD without BRCA 1 or BRCA 2 mutations 
have similar histology, biology and clinical features of BRCA mutated tumours (so called 
BRCAness phenotype [31] [32] [33]). Unfortunately, nowadays a standardized test that can 
optimally identify HRD EOCs does not exist, even if several strategies were attempted. Among 
them some have tried to identify directly the key mutations in HR pathway with gene expression 
profiles of DNA repair proteins using “targeted capture and massively parallel sequencing” (e.i. 
BROCA profile) [34] [35] [36]. Other tests used indirect ‘scars’ [37], such as mutational signatures 
[38] or structural variations of the genome, identified as genome variation larger than 100 kb, that 
result from DSB in cells with HRD [37]. The most important “scars” used in HRD tests are: 
 Numerical chromosomal instability (CIN), an amplification or deletion of large fragments of 
chromosomes, usually interesting a whole chromosome arm [39] [40] [41]; 
 Somatic rearrangement pathways related to specific DNA-repair deficiency, for example 
tandem duplications (TDs) [42] ; 
 Loss of Heterozygosis (LOH) of multiple megabasis fragments [43], used as marker of HRD 
in several trials as discussed below [26] [44]. 
 A combination of three variables: intermediate size LOH (>15 Mb) added to allelic 
imbalance that involve the telomerase (TAI) and number of chromosomal breaks longer than 
10 Mb [45] [27].  
 
1.2. PARP family and PARP inhibitors Mechanism of action 
In the complex landscape of DNA repair mechanism, PARP family plays a central role [46]. PARPs 
are a group of enzymes that transfer polyADP-ribose from NAD+ to some target proteins in a post 
transcriptional process known as PARylation [47]. Among them, PARP-1, 2 and 3 are the most 
extensively studied. PARP-1, that accounts for up to 90 % of the entire PARP activity, recruits 
DNA repair complex in BER [48], detects disruptions in replication forks [49], PARylates essential 
proteins involved in HR [50] (e.i. BRCA1 recruitment to sites of DNA damage [51]) and acts as a 
negative regulator in NHEJ [52] [53], with the cooperation of  PARP-2 and PARP-3 and plays a 
central role in microhomology-mediated end joining repair, an error-prone pathway involved in 
DSBs repair [52] [53]. Beyond DNA repair PARPs are also involved in transcriptional regulation, 
mitosis, cell death, telomere length and intracellular metabolism [54]. 
PARPis are generally benzamide or purine based analogues of nicotinamide that compete with 
NAD+ in the catalytic domain of PARPs [55] [56]. Their activity is historically based on the 
concept of “synthetic lethality”, first introduced in 2005, according to which two genetic lesions, 
not lethal when individually present, become lethal if both occur in the same cell. For this reason 
cells that are HR deficient are more sensitive to PARP activity inhibition [50] [57] [58]. PARP 
inhibition reduces both HR and BER activity, thus SSBs remaining unrepaired [59], leading to a 
high number of DSBs that are not repaired in HRD cells during DNA duplication [59]. PARPis 
prevent also the inhibition of NHEJ, with a high load of mutations and cell apoptosis [60]. Figure 1 
resumes the principal PARPis  mechanisms of action above described. 
All PARPis [54] [61] developed in EOC are PARP-1 and PARP-2 inhibitors, while Olaparib and 
Rucaparib inhibit also PARP-3 and Rucaparib inhibits also tankyrase-1, another member of PARP 
family[62] [63]. 
Recent studies show that PARP inhibition is more cytotoxic that genetic depletion of PARPs, 
finding that PARPis “stabilized” PARP-1 and PARP-2 DNA complexes. This activity, known as 
PARP trapping, prevents DNA repair, leading to cell death [62]  [63]. Murai et al demonstrated that 
PARP trapping is strongly related to PARPis cytotoxic activity [62] [63] [64]. Despite of similar 
PARP catalytic inhibitory activities, Talazoparib shows the greatest in vitro cytotoxicity and PARP-
trapping [63], followed by Niraparib. Olaparib and Rucaparib show a medium citotoxicty and 
PARP-trapping, whereas Veliparib is the weakest one [4] [62]. These differences are probably due 
to allosteric differences in NAD+ binding site; Niraparib and Olaparib are bulky inhibitors 
compared to Veliparib, while Talazoparib has  a rigid structure if compared to  the “flexible” 
Olaparib and Rucaparib [62] [63]. 
The aim of this review is to describe the rationale beyond development of PARPis, their mechanism 
of action and the most important clinical trial that led to their approval in clinical practice. 
Moreover, we report an overview and future perspectives of these new molecules summarizing the 
ongoing clinical trial with PARPis. To do this we operated a search on clinicaltrials.gov with 
“ovarian cancer” and the single name of each compound (Olaparib, Niraparib, Rucaparib, Veliparib 
and Talazoparib) as keywords. 
 
2. OLAPARIB 
2.1. Description 
Olaparib (@Lynparza, Astra Zeneca), known as AZD2281, is an inhibitor of the mammalian 
polyadenosine 5’-diphosphoribose polymerase (PARP) enzymes 1, 2 and 3 (PARP 1, PARP2 and 
PARP 3 respectively). Its chemical name is 4-[(3-{[4-(cyclopropylcarbonyl) piperazin-1-
yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)] one and the chemical structure is showed in 
Figure 2. Olaparib molecular formula is C24H23FN43 and has a molecular mass of 434.46 amu. 
Lynparza has a low, pH-indipendent, solubility, with a value of nearly 0.1 mg/ml in the normal pH 
range. 
The molecule is disposable for oral use as capsules since 2014, each one containing 50 mg of 
Olaparib associated with some excipients [65].  Since August 2017, after the publication of SOLO-2 
study results (see below for the details), also a tablet formulation is available in two different 
dosages, containing respectively 100 mg and 150 mg of Olaparib 
 
2.2. Pharmacokinetics 
Comparing tablet and capsule formulation the bioavailability is higher for the tablets, with a steady 
state exposure (AUC) 77% higher after 300 mg tablet twice daily in comparison after 400mg 
capsule twice daily. After a single dose of 300 mg tablet the geometric mean AUC is 42 μg*h/ml, 
while Cmax is 5.8 μg/ml, while the steady state data are 49 μg*h/ml and 7.7 μg/ml respectively. In 
the pharmacodynamics studies no clinically relevant alterations of cardiac repolarization neither 
modification in QT interval were reported[66].   
Absorption 
After oral intake the median peak plasma concentration is established after 1.5 hours. The co-
administration of high fat meals prolonged that time, with a delay of 2.5 hours in the absorption, but 
no significant alteration in the amount of absorption was reported, except an increased mean AUC 
of nearby 8%. 
Distribution 
The mean (±SD) apparent volume of distribution is 158±136 L after a single intake of 300 mg of 
Olaparib, with an in vitro protein binding nearly 82%. 
Metabolism 
The two enzymes mostly involved in Olaparib metabolism are CYP3A4 and CYP3A5. For that 
reason, concomitant use of strong or moderate CYP3A inhibitors should be avoided. Oxidation 
reactions are fundamental in the metabolism and the great part of metabolites are produced with 
glucuronide or sulfate conjugation.  
Excretion 
After a single 300 mg dose the mean (±SD) plasma half-life is 14.9 ±8.2 hours, with an apparent 
plasma clearance of 7.4 ± 3.9 L/h. In an experiment with 
14
C-Olaparib, 86% of radioactivity is 
redeemed in 7 days, 44% through urine and 42% through feces, with the most of compound 
excreted as metabolites [67]. 
2.3. First evidence of clinical activity 
Olaparib was the first small-molecule oral PARP inhibitor developed in ovarian cancer. Back in 
2009 a phase I trial by Fong and colleagues reported a low side effect profile (fatigue, nausea and 
anaemia in 30%, 32% and 5% of patients respectively) associated with a clinical benefit of 63 % in 
BRCA 1/2 mutated population (19 patients) [68].  One year after the same study-group presented a 
single-stage expansion of the phase I trial exploring the drug in 50 ovarian cancer BRCA-mutated 
patients. Forty per cent of patients had a radiological or serological response, while the overall 
clinical benefit rate (CBR) was 46%. Interestingly, for the first time, a correlation was reported 
between CBR and PFI; moreover, a post hoc analysis pinpointed an association of platinum 
sensitivity with Olaparib response both at radiological and serological level (p = 0.001 and p= 0.002 
respectively) [69]. Despite the achievement of responses at a dose of 100 mg twice daily, Audeh 
and colleagues conducted a proof-of concept phase II trial in order to compare objective response 
rate (ORR) of this dosage with the maximum tolerated dose of 400 mg twice daily in a population 
of 57 heavily pretreated germline BRCA mutated (gBRCAm) ovarian cancer patients. ORR was 
33% in the cohort treated with 400 mg twice daily vs 13% in the cohort treated at the lower dose; 
the median progression free survival (PFS) was 5.8 months (95% confidence interval CI 2.8-10.6) 
versus 1.9 months (95% confidence interval CI 1.8-3.6) in favor of 400 mg twice daily. The 
treatment at higher dose was well tolerated, with a slight increase in nausea, fatigue and anemia. 
Therefore 100 mg bis in die (bid) dose seems to be less effective than 400 mg bid. It must be 
noticed that allocation of patients was not randomized and the 100 mg bid group had worse 
prognostic characteristics [70]. 
The better efficacy of the higher dose of 400 mg bid was confirmed by the first randomized phase II 
trial, known as Study 12. The study enrolled 97 gBRCAm ovarian cancer patients relapsed within 
12 months of previous platinum therapy and assigned them to receive Olaparib 200 mg or 400 mg 
continuously, both dose twice daily, or PLD 50 mg/m2 day 1/28. Neither median PFS or ORR 
between Olaparib groups and PLD group reached statistical significance [71]. 
Olaparib seems to be active also in BRCA wild type ovarian cancer, as demonstrated for the first 
time in 2011 by Gelmon in a phase II trial, with a ORR of 24% versus the 41% reported in the 
gBRCAm patients [72]. These data confirmed the hypothesis that HRD and consequent 
susceptibility to platinum compounds or other drugs that create DNA damage, like PLD, or prevent 
damage repair, like PARPis, depend on various gene alteration and not only on BRCA mutation 
[28].  
2.4. Pivotal trials for Olaparib approval 
Olaparib monotherapy efficacy as a maintenance treatment was ratified in two randomized clinical 
trials, with more than 500 patients enrolled worldwide, known as Study 19 and SOLO 2, at the dose 
of 400 mg twice daily (capsules) and 300 mg twice daily (tablets), respectively. 
In 2012 Lederman and colleagues [73] presented the first results of a double-blind, placebo-
controlled phase II trial that enrolled 265 platinum-sensitive ovarian cancer patients previously 
treated with two or more platinum based chemotherapies and a complete or partial response 
achieved to the last platinum therapy. Patients were randomized to receive @Lynparza capsules 400 
mg twice daily or placebo and the stratifications were done by response to the last platinum 
compound (complete versus partial), time to progression on penultimate platinum line and ancestry 
(Jewish versus non-Jewish). The primary endpoint of this trial was investigator-assessed PFS. PFS 
was significantly prolonged in the Olaparib group, 8.4 versus 4.8 months and a hazard ratio (HR) 
0.35 (95% CI 0.25-0.49, p<0.00001). The first analysis of overall survival (OS), a secondary 
endpoint, showed no difference, although a pre-planned subgroup analysis seemed to highlight an 
advantage for patients with a known BRCA mutation. These modest results led to a “dark period” 
for Olaparib development because no drugs authorities would approve it in absence of greater and 
certain benefit [74]. In order to develop a “target therapy” meanwhile data on germline BRCA 
mutation status were derived from a retrospective analysis and showed that 36% of the enrolled 
population (96 patients) were mutated, 53 in the Olaparib group (39%) and 43 in the placebo group 
(33%). This new information opened a new lucky era for Olaparib two years later, with the results 
of a preplanned-subgroup efficacy analysis based on BRCA status. The effect of Olaparib in BRCA 
mutated patients was greater and lead to a PFS of 11.2 months versus 4.3 months observed in 
BRCA wild type (HR 0.18, 95% CI 0.10-0.31, p<0.00001). A significant, even if smaller, benefit 
was reported also for BRCA wild type treated with Olaparib compared to the placebo group (7.4 
versus 5.5 months, HR 0·54, 95%IC 0.34-0.85, p=0.0075) [75]. Nor in the second [75] neither in 
the third interim analysis [76] a significant difference in OS was reported and this was probably due 
to the high rate of crossover (23%). In this phase II study Olaparib showed a good tolerability 
profile with a dose interruption rate of 36% versus 16% in the placebo group; the grade 3 or worse 
side effects reported were fatigue, nausea and anemia. In patients treated for two years or more 75% 
reported low-grade nausea, 56% experienced fatigue, 38% vomiting and 25% anaemia. 15% of the 
BRCA mutated patients continued Olaparib for at least 5 years. 
Since preclinical data proved that Olaparib could increase the efficacy of DNA-damaging 
chemotherapy, in 2015 Oza and colleagues [77] investigated this hypothesis and published the 
results of a randomized, open-label, phase II study in which, 162 platinum-sensitive, recurrent 
ovarian cancer patients, pre-treated at least with three previous platinum based chemotherapy lines 
were randomized to receive a) Olaparib 200 mg capsules twice daily from day 1 to 10 of a 21-day 
cycle in association with carboplatin AUC 4mg/ml/min and paclitaxel 175 mg/m2 on day 1/21 
followed by Olaparib monotherapy (400 mg capsules twice daily given every day until progression; 
or b) carboplatin AUC 6 mg/ml/min and paclitaxel 175 mg/m on day 1/21 followed by none 
maintenance therapy. BRCA status was known or retrospectively retrieved for 107 patients; 38% 
were mutated and equally divided between the two arms of treatment. PFS was greater in the 
Olaparib arm, with a median of 12.2 versus 9.6 months (HR 0.51, 95% CI 0.34-0.77, p=0.0012), 
with a highly regarded advantage in BRCA mutated patients (HR 0.21, 95% CI 0.08-0.55, 
p=0.0015). The most common grade 3 or higher side effects during the association phase were 
neutropenia (43% versus 35 % in the chemotherapy alone group) and anemia (9% versus 7%), 
whereas serious adverse events were more frequently reported in the chemotherapy alone group 
(21% versus 15%).  
The endorsement of Olaparib primary role to prolong PFS and time to first and second subsequent 
chemotherapy arrived with the publication of the randomized, double-blind, phase III trial 
conducted by Pujade-Lauraine et al. The SOLO-2 trial enrolled 295 gBRCAm patients and 
randomized them to receive Olaparib tablets 300 mg twice daily versus placebo after a partial or 
complete response to the most recent platinum based chemotherapy. Also in this trial, all patients 
were pre-treated with two or more platinum containing chemotherapy, with a nearly 40% of highly 
pretreated (three or more previous line) in the Olaparib group. Investigator assessed-PFS, the 
primary endpoint, was longer in patients treated with @Lynparza, with a median of 19.1 versus 5.5 
months (HR 0.30, 95% CI 0.22-0.41, p<0.0001)[25]. The advantage was seen in all subgroups, also 
in the patients pretreated with bevacizumab. As reported in the poster session of ESMO 2017 
Congress, the superiority is reported also in the most heavily pre-treated patients with no statistical 
significant interaction between number of prior lines of platinum-based therapy received and PFS 
benefit [78]. Olaparib met also two secondary endpoints, actually considered OS surrogates, the 
time to first and second subsequent therapy, with HR 0.28 (95% CI 0.21-0.38, p<0.0001) and HR 
0.37 (95% CI 0.26-0.53, p<0.0001), respectively. Moreover, Olaparib had no significant detrimental 
effect on health-related quality of life (HRQoL) [25] [79]. The most frequently reported side effects 
of CTCAE were low grade nausea, asthenia, vomiting, abdominal pain and diarrhea in both groups. 
The most common adverse event of grade 3 or higher in the Olaparib group was anemia, with blood 
transfusion rate of 18% versus 1% in the placebo group, whereas neutropenia and thrombocytopenia 
of grade 3 or worse severity were similar in the two groups.  
Olaparib demonstrated to be effective also as monotherapy in a single arm study conducted by 
Kaufman [80], well known as Study 42, where 298 patients with deleterious or suspected 
deleterious gBRCAm patients with different kind of tumors, including 193 ovarian cancer patients 
heavily pre-treated (median of prior chemotherapy lines was 5). The ORR was 34% with a median 
duration of response (DOR) of 7.9 months. Domchek et al. published additional data about EOC 
gBRCAm population of this trial, focusing on the 137 patients with measurable disease and 
pretreated with three or more chemotherapy lines. ORR in platinum-resistant tumors was 30%; 
interestingly, although the median DOR was similar for platinum-sensitive and platinum-resistant, 
the platinum sensitive population achieved better outcome across all the endpoints [81]. 
Efficacy of Olaparib treatment, considering both ORR and DOR, was confirmed also by a pooled 
analysis on 300 gBRCAm EOC patients conducted by Matulonis and colleagues, with a similar and 
manageable safety profile in more heavily pretreated patients (≥3 lines of prior chemotherapy) [82]. 
  
2.5. Indication and dosage 
Olaparib (@Lynparza) has been approved by FDA and EMA as maintenance therapy for recurrent 
epithelial ovarian, fallopian tube or primary peritoneal cancer after the achievement of a complete 
or partial response to chemotherapy with a platinum compound in patients with a somatic or 
germline mutations in BRCA 1 or 2 genes. The results presented by Kauffman [80] in December 
2014 led to faster FDA approval  to use olaparib as monotherapy in gBRCAm patients after at least 
three prior lines by. 
As reported previously Olaparib is available both as capsules and tablets. Based on the different 
pharmacokinetics and biovailability is not possible to change from one formulation to another on a 
milligram-to-milligram basis.  The approved dose for oral intake of @Lynparza is 300 mg (two 150 
mg tablets) twice daily, with or without food, for a total daily dose of 600 mg. If tablets formulation 
is not yet available, the recommended capsules dose is 400 mg (eight 50 mg capsules) twice daily 
[83]. The treatment should be carried on until disease progression or unacceptable toxicity [66]. 
2.6. Current strategies of development 
The recruiting, or about to recruit, ongoing clinical trial summarized in Table 1 would answer to 
some fundamental still pending questions on PARPi, and consequently, on Olaparib use. First of all, 
since the outmost important aim is to increase the cure rate, we are looking for results of SOLO 1 
trial, where Olaparib in BRCAm patients is administered after the first line chemotherapy. 
Secondly, while today maintenance seems to be the right way to use this compound, some ongoing 
trials would give us data about the best treatment sequence (chemotherapy upfront versus PARP-I 
followed by chemotherapy). Moreover, it is important to investigate efficacy and safety of the 
possible combinations with promising new therapies for EOC like immunotherapy and 
antiangiogenic agents. The first encouraging clinical data on association of Cediranib, an oral 
tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor with Olaparib were 
reported by Liu et al. The combination arm (Olaparib 200 mg twice daily associated with Cediranib 
30 mg daily) achieved longer PFS then the control arm with Olaparib monotherapy (17 months 
versus 9 months, p=0.005) [84]. Lastly, we do not have data on rechallenge role in Olaparib pre-
treated patients.  
 
 
3. NIRAPARIB 
3.1. Description 
Niraparib (@Zejula, TESARO Inc.), formerly known as MK-4827, is an orally active and potent 
PARP inhibitor. The chemical name of Niraparib is tosylate monohydrate is 2-{4-[85]phenyl}-2H- 
indazole 7-carboxamide 4-methylbenzenesulfonate hydrate (1:1:1). The molecular formula is 
C26H30N4O5S and it has a molecular weight of 510.61 amu (Figure 3). Niraparib solubility is pH 
independent below the pKa of 9.95, with an aqueous free base solubility of 0.7 mg/mL to 1.1 
mg/mL across the physiological pH range. Each @Zejula capsule contains 159.4 mg niraparib 
tosylate monohydrate equivalent to 100 mg Niraparib free base as the active ingredient [86].  
 
 
3.2. Pharmacokinetics 
Niraparib pharmacokinetics and first-in-humans activity was assessed in the phase I trial by Sandhu 
et al. [87]. 300 mg/day was established as the maximum tolerated dose.  
Following a single-dose administration of 300 mg the mean (±SD) peak plasma concentration 
(Cmax) was 804 (± 403) ng/mL. The systemic exposures (Cmax and AUC) of Niraparib increased 
in a dose proportional manner, with daily doses ranging from 30 mg (0.1 times the approved 
recommended dosage) to 400 mg (1.3 times the approved recommended dosage).  
Absorption 
The absolute bioavailability of Niraparib is approximately 73%. Following oral administration of 
Niraparib, peak plasma concentration, Cmax, is reached within 3 hours. Concomitant administration 
of a high fat meal (800-1,000 calories) does not significantly affect the pharmacokinetics. 
Distribution 
Niraparib is 83.0% bound to human plasma proteins. The average (±SD) apparent volume of 
distribution (Vd/F) was 1220 (±1114) L. 
Elimination 
Following multiple daily doses of 300 mg Niraparib, the mean half-life (t1/2) is 36 hours. In a 
population pharmacokinetic analysis, the apparent total clearance (CL/F) was 16.2 L/h. 
Metabolism 
Niraparib is metabolized primarily by carboxilesterase (CEs) to form a major inactive metabolite, 
which subsequently undergoes glucuronidation. 
Excretion 
Following administration of a single oral 300 mg dose Niraparib, the average percent recovery of 
the administred dose over 21 days was 47.5% (range 33.4% to 60.2%) in urine, and 38.8% (range 
28.3% to 47.0%) in feces. 
3.3. Clinical activity 
The activity and safety of Niraparib monotherapy 300 mg once daily was first explored in the phase 
I trial by Sandhu and colleagues. Dose-limiting toxic effects were grade 3 fatigue, grade 3 
pneumonitis, and grade 4 thrombocytopenia. Common treatment-related toxic effects were anaemia 
(48%), nausea (42%), fatigue (42%), thrombocytopenia (35%), anorexia (26%), neutropenia (24%), 
constipation (23%), and vomiting (20%), and were predominantly grade 1 or 2. Pharmacodynamic 
analyses confirmed PARP inhibition exceeded 50% at doses greater than 80 mg/day and antitumour 
activity was documented beyond doses of 60 mg/day. Antitumor activity beyond HGSOC was also 
reported in non-small-cell lung cancer and prostate cancer [87]. Trial 1 (ENGOT-OV16/NOVA) 
was the first phase III trial designed and has studied Niraparib efficacy in 367 patients with 
platinum-sensitive recurrent ovarian, fallopian tube, and primary peritoneal cancer in [27]. The 
NOVA trial was a double-blind, placebo-controlled trial in which EOC patients (n=553) were 
randomized 2:1 to Niraparib 300 mg orally daily or matched placebo within 8 weeks of the last 
therapy. All patients had received at least two prior platinum-containing regimens and were in 
response (complete or partial) to their most recent platinum-based regimen. Randomization was 
stratified by time to progression after the penultimate platinum therapy (6 to <12 months and ≥12 
months), use of bevacizumab in conjunction with the penultimate or last platinum regimen (yes/no) 
and best response during the most recent platinum regimen (complete versus partial response). 
Eligible patients were assigned to one of two cohorts based on the results of the BRACAnalysis 
CDx. Patients with deleterious or suspected deleterious germline BRCA mutations (gBRCAm) were 
assigned to the germline BRCA mutated (gBRCAmut) cohort (n=203), and those without germline 
BRCA mutations were assigned to the non-gBRCAmut cohort (n=350). The major efficacy outcome 
measure, PFS, was determined primarily by central independent assessment per RECIST (Response 
Evaluation Criteria in Solid Tumors, version 1.1). Results showed that PFS in the Niraparib group 
was significantly longer than in the placebo group in all three primary efficacy populations 
(P<0.001). In the gBRCA cohort, median PFS was 21.0 months in the Niraparib group and 5.5 
months in the placebo group (HR 0.27). Moreover, Niraparib treatment resulted in significantly 
longer PFS in both the HRD-positive subgroup of the non-gBRCA cohort (median 12.9 months vs. 
3.8 months) and in the overall non-gBRCA cohort (median 9.3 months vs. 3.9 months). Adverse 
reactions in the NOVA trial led to dose reduction or interruption in 69% of patients, most frequently 
for thrombocytopenia (41%) and anemia (20%). Analyses of patient-reported outcomes (PRO) 
indicated similar outcomes for those receiving Niraparib and those receiving placebo. The 
permanent discontinuation rate due to adverse reactions was about15%. The median exposure to 
Niraparib in this cohort was 250 days.  
Following these results several post hoc and subgroups analyses have already been done. First of 
all, Matulonis and colleagues analyzed data from the NOVA trial to determine the long-term 
efficacy of Niraparib and its impact on subsequent therapy [88]. Results showed that Niraparib was 
associated with a superior estimated PFS probability at 12, 18, and 24 months, regardless of 
patient’s BRCA mutation status, suggesting that patients who had received treatment with Niraparib 
were not resistant to subsequent therapy. Secondary, Mirza et al. presented results of a post hoc 
analysis of efficacy, safety, and PRO from a subset of patients in the NOVA trial who achieved a 
PR after their last platinum-based chemotherapy (n=272) [89]. A comparison of the PFS and 
Quality of life (QoL) HRs showed no difference between the overall population and patients who 
achieved a PR to their most recent platinum-based chemotherapy. Moreover, Dr. José Del Campo 
and colleagues evaluated platinum sensitivity and outcomes in patients assigned to the placebo arm 
in the NOVA trial [90]. Patients who experienced disease progression within 6 months after their 
last platinum-based regimen had received more prior lines of platinum-based therapy, as well as 
more lines of any chemotherapy, compared with patients whose remission lasted 6 months or 
longer. Among patients with germline BRCA1/2 mutation, 46% of those progressing within 6 
months and 39% of those progressing at 6 months or later received 3 or more lines of platinum-
based therapy, and 63% vs 45%, respectively, received 3 or more lines of any type of 
chemotherapy. Among BRCA1/2 wildtype patients, 29% of those who progressed within 6 months 
and 15% of those who progressed at 6 months or later received 3 or more lines of platinum-based 
therapy, and 43% vs 19%, respectively, received at least 3 lines of any chemotherapy, indicating 
that a substantial number of patients with platinum resistant ovarian cancer was included in the 
NOVA trial. Finally, more recently Mirza at the European Society of Gynecologic Oncology 
Meeting 2017 presented data showing how in the NOVA trial thrombocytopenia grade 3-4 
correlated with patients weight (if <67kg) and myelosuppression during the prior chemotherapeutic 
regimen[91]. These data belong to a retrospective analysis, thus further investigations are required 
to better tailor Niraparib dosage in the real clinical practice setting. 
3.4. Indication and dosage 
Following the results of the NOVA trial [27] Niraparib (@Zeyula) received both FDA and EMA 
approval
 
as maintenance treatment of adult patients with recurrent EOC, fallopian tube, or primary 
peritoneal cancer in a complete or partial response to platinum-based chemotherapy, regardless 
BRCA status and number of previous lines of treatment. The recommended dose is 300 mg once 
daily. Patients should start treatment within 8 weeks after their most recent platinum-containing 
regimen and treatment should be continued until disease progression or unacceptable toxicity [86]. 
3.5. Current strategies of development 
Niraparib combinations with molecular-targeted agents and cytotoxic agents are under investigation 
and in some cases have moved to the clinical trial phase. Several clinical trials are actually ongoing 
both in platinum-sensitive and platinum-resistant setting, investigating the activity of Niraparib 
single agent as first line therapy or Niraparib in association with anti-PD1 and anti-VEGF agents 
(Table 2). 
 
4. RUCAPARIB 
4.1. Description 
Rucaparib (@Rubraca, Clovis) also known as AG-014699 and PF-01367338 is an oral PARP-1, 2 
and 3 inhibitor. Its molecular formula is C19H18FN3O and its chemical name is 8-fluoro-2-(4-
((methylamino)methyl)phenyl)-4,5-dihydro -1h-azepino [5,4,3-cd]indol-6(3H)-one. The molecular 
mass of Rucaprib is 555.67 Daltons. As previously reported this drug differs by others PARP 
inhibitors because of its inhibitory activity also on other enzymes involved in homologous 
chromosomal recombination called tankyrases [63].  The chemical structure of Rucaparib is 
reported on Figure 4 [92]. 
4.2. Pharmacokinetics 
The pharmacokinetics, safety and activity of oral Rucaparib were evaluated in 56 patients, primarily 
affected by breast or ovarian cancer, enrolled by Kristelet et al in a phase I/II trial (Study 1) [93]. 
Absorption The median time to reach maximum concentration (Cmax) is  1.9 hours at the approved 
dosage. The mean absolute bioavailability of Rucaparib immediate-release tablet is 36% with a 
range from 30% to 45%. Following a high-fat meal, the Cmax increases by 20%, and the time to 
reach C max is prolonged by 2.5 hours  [92] [94]. 
Distribution The protein binding of Rucaparib observed in vitro was 70% in human plasma at 
therapeutic concentrations. Rucaparib preferentially distributed to red blood cells with a blood-to-
plasma concentration ratio of 1.83. 
Elimination The mean terminal half-life after a single oral dose of Rucaparib ranges from 17 to 19 
hours. The apparent clearance ranges from 15.3 to 79.2 L/hour with 600 mg Rucaparib twice daily. 
Metabolism Rucaparib is metabolized by CYP2D6 and to a lesser extent by CYP1A2 and 
CYP3A4. 
Excretion Rucaparib is excreted mainly through the faeces, accounting for >= 79% of the total 
dose. 
4.3. Clinical activity 
The efficacy of Rucaparib in monotherapy for the treatment of EOC was first assessed in two 
multicentre single arm trial, the phase I/II study, named Study 1 (NCT01482715) and the phase II 
trial Study 2 (ARIEL2). In the first part of study 1, as previously reported, 56 patients were enrolled 
and the 35,7% of them was affected by platinum sensitive or platinum resistant ovarian cancer. One 
patient with platinum sensitive EOC achieved a complete response and two patients with a platinum 
resistant EOC obtained a partial remission. No grade 4 adverse events were observed. The most 
common drug-related toxicities reported were fatigue, gastrointestinal disorders, myelotoxicity, 
hyporexia, and elevation of transaminase levels. In the second part of the trial authors evaluated the 
activity of Rucaparib in 42 patients with platinum sensitive ovarian cancer with BRCA1/2 germline 
mutations. This population reported an objective response rate of 59.5% and a median duration of 
response of 7.8 months (range 5.6-10.5)  [93] [95]. 
In the first part of the phase II ARIEL 2 trial 204 patients with recurrent platinum sensitive EOC 
were enrolled and classified in three subgroups on the basis of HRD status (BRCA mutated (n=40), 
LOH high (n=82), LOH low (n=70). All patients were treated with 600 mg of oral Rucaparib twice 
daily. A median PFS of 12.8, 5.7 and 5.2 months was observed respectively in the three subgroups. 
The difference observed between patients harboring BRCA mutation or with LOH high was 
significantly greater than in the low LOH group. The most common grade 3 or worse toxicities 
observed were anemia and transaminase increase [26]. The second part of ARIEL 2 trial is still 
ongoing; 286 patients who have received at least 3 lines of chemotherapy with both platinum 
sensitive or platinum resistant disease have been enrolled to evaluate clinical activity of Rucaparib 
in this different setting based on HRD status. In another phase II trial Drew et al investigated 
intermittent and continuous schedules of intravenous or oral Rucaparib in 78 patients with advanced 
breast or ovarian cancer harbouring BRCA1/2 mutations. The ORR for oral Rucaparib (across all 
dose levels) was 15%. 12 out of 13 patients treated with continuous oral Rucaparib obtained a 
CR/PR or SD for more than12 weeks, with a median duration of response of 179 days.  The 
intermittent intravenous Rucaparib resulted in an ORR of only 2%. However, 41% of patients 
achieved SD for longer than 12 weeks, with 3 patients maintaining disease stabilisation for more 
than 52 weeks. All the 51 patients with ovarian cancer enrolled in this study have been previously 
treated with a platinum-based chemotherapy; authors observed a correlation between response rate 
to Rucaparib and PFI.  No response was reported among breast cancer patients. The half-life of 
Rucaparib after oral dosing reported in this study was 9.1±2.7hours. The most common reported 
adverse events were fatigue and nausea [96]. 
The results of the phase III trial ARIEL 3 have been recently published. In this randomized, double-
blind, study 564 patients with platinum sensitive EOC in response after their last platinum-based 
chemotherapy were treated with Rucaparib 600 mg twice daily or placebo.  Authors reported a 
prolonged PFS in patients assigned to the experimental arm. For BRCA mutated patients median 
PFS was respectively of 16.6 months in the Rucaparib arm versus 5.4 months in the placebo group.  
A significant increase in PFS was also observed in patients without BRCA mutation, PFS reported 
for patients with a HRD carcinoma treated with Rucaparib was 13. 6 months vs 5.4 for the placebo 
group while in the intention to treat population was 10.8 versus 5.4 months. Grade 3-4 adverse 
events were more frequent in the experimental arm (56% vs 15%) and the most common were 
anaemia and transaminase elevation [44]. 
4.4. Indication and dosage 
Rucaparib have been approved by the FDA as a single agent for the treatment of patients affected 
by relapsed ovarian cancer with germline or somatic BRCA mutations who have been treated with 
two or more lines of chemotherapy. The recommended phase II dose of single-agent oral Rucaparib 
is 600mg twice daily [93]. Based on the results of ARIEL 3 trial, Clovis Oncology have recently 
submitted a supplemental New Drug Application (sNDA) for a second-line and later maintenance 
treatment indication for patients with recurrent platinum-sensitive EOC in response to their most 
recent platinum therapy 
4.5. Current strategies of development  
Rucaparib is actually the only PARP inhibitor approved in monotherapy regardless of platinum 
sensitivity, following the publication of the results of Study 1 and ARIEL 2 demonstrating the 
efficacy in monotherapy in patients with recurrent BRCA mutated EOC. Considering the fewer 
available options of treatment for patients with platinum resistant disease NCCN guidelines 
recommends Rucaparib single agent also in this setting in presence of BRCA mutations [97]. As 
previously reported it is feasible that early Rucaparib will also be approved as maintenance therapy 
in patients with platinum sensitive relapsed EOC in response to their last platinum-based 
chemotherapy. Several trials investigating the activity of Rucaparib, both as a single agent and after 
platinum based chemotherapy for treatment of ovarian cancer, are ongoing. A phase I study 
evaluating the association of Rucaparib and the anti-PD-L1 Atezolizumab is actually recruiting 
patients. The others ongoing clinical trials are summarized in Table 3. 
5. TALAZOPARIB 
5.1. Description 
Talazoparib (also known as MDV3800 and BMN 673) is a selective inhibitor of PARP1 and2. The 
molecular formula of Talazoparib  is C19H14F2N6O and its chemical name is (8S,9R)-5-fluoro-8-
(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-
3(7H)-one. The molecular weight is 380.359 g/mol. The chemical structure of Talazoparib is shown 
in Figure5. 
5.2. Pharmacokinetics 
The antitumor activity and pharmacokinetics of Talazoparib was evaluated for the first time by De 
Bono et al in a 2-stage dose-escalation trial [98]. In the first part of this study 39 patients with 
BRCA mutated tumors were enrolled in 9 cohorts from 25 to 1100 µg/d.  The maximum tolerated 
dose was defined at 1000 µg/d. An inhibitory activity against PARP was reported at doses ≥ 100 
µg/day in PBMCs. Steady state plasma concentrations were reached by the end of the second  week 
of daily dosing; the maximum plasma concentration was reached within 2 hours after all evaluated 
doses .  
Absorption 
In a subsequent dose-escalation phase I study [99] conducted in patients with BRCA 1 or 2 
mutations Talazoparib has shown to have a rapid absorption. The maximum plasma concentration 
(Cmax) was reached within 2 hours after all evaluated doses. 
Distribution  
Talazoparib has demonstrated to be well distributed into tissues, and its volume of distribution 
seems to be in excess of the volume of the systemic circulatory space.  
Elimination 
The half-life observed at the MTD dose of 1.0 mg/day was nearly 48 hours.  
Excretion 
Results for urinary elimination of the parent compound suggest linear urinary elimination kinetics 
after daily Talazoparib dosing between the 0.025 and 1.1 mg dose levels 
5.3. Clinical activity 
The evaluation of Talazoparib activity in the treatment of ovarian cancer is still at an early stage. In 
2016 Dhawan et al. presented the results of a phase I/II trial evaluating Talazoparib in combination 
with carboplatin in patients with solid tumors with or without germline mutations. Among the 24 
patients enrolled, 2 patients (8%) were affected by EOC and 20% were BRCA1/2 mutant cases. Other 
grade 3/4 toxicities reported were fatigue (13%), neutropenia (63%), thrombocytopenia (29%), and 
anemia (38%). A deeper decrease of the neutrophil count was observed in patients with germline BRCA 
mutations. Authors reported 1 CR and 2 PR among BRCA mutated patients. Four patients maintained a 
stable disease beyond 4 months; 3 of them had a somatic BRCA mutation and the fourth had a BRIP 
germline [100]. 
De Bono et al investigated the safety pharmacokinetics and activity of Talazoparib in a phase I/II dose-
escalation trial enrolling patients with germline BRCA1 or 2 mutated tumors or selected patients with 
sporadic cancers. A sustained PARP inhibition was observed at doses ≥0.60 mg/day.  The most 
common possibly related adverse event observed were fatigue; nausea; anemia; neutropenia; 
thrombocytopenia and grade 1 alopecia. A dose-limiting thrombocytopenia was observed 
respectively in 1/6 and 2/5 patients at 900 and 1100 µg/d.  In this trial 34 EOC patients were enrolled, 
25 of them with germline BRCA mutated, all previously treated with platinum based chemotherapy 
were enrolled, 12 of them with measureable disease. Among them 42% had an objective response rate 
and 67% add a clinical benefit rate with a median PFS of 36.4 weeks [99].  
Results from phase II or III in patients with EOC are not available. However regarding patients with 
BRCA mutations encouraging signs about the efficacy of Talazoparib came from a phase II study 
conducted in  patients with BRCA positive breast cancer (ABRAZO) in which an ORR of 24% and 
34% respectively was reported for BRCA 1 and BRCA 2 mutations carriers [101].  
5.4. Current strategies of development 
Evidences supporting the use of Talazoparib in the treatment of EOC are few in comparison with 
other PARPis. However some studies evaluating the activity of Talazoparib in ovarian carcinoma 
are ongoing (Table 4), including a phase 1 study in association with a checkpoint inhibitor and a 
phase II study exploring Talazoparib activity in advanced cancers with BRCA1/2 germline or 
somatic alterations, PTEN mutations or PTEN loss and HRD defect. 
 
6. VELIPARIB 
6.1. Description 
Veliparib, also called ABT-888, is a poly(ADP-ribose) polymerase (PARP) -1 and -2 inhibitor with 
chemosensitizing and antitumor activities. Veliparib has no antiproliferative effects as a single 
agent. The molecular formula of Veliparib is C13H16N4O and its IUPAC name is 2-[(2R)-2-
methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide. The chemical structure of Veliparib is 
reported in Figure 6.  
6.2. Pharmacokinetics 
The pharmacokinetics of Veliparib was assessed by Kummar et al in phase 0 trial. They observed 
that the absorption peak occurs after 0.5–1.5 hours with a single dose of 50 mg [102]. In a phase I 
trial presented by Puhalla et al in 2014 the half-life of Veliparib was assessed at 5.2 hours [103]. 
Absorption  
Veliparib demonstrated to have a good oral bioavailability, and a peak absorption between 0.5 and 
1.5 hours, with a C max of 0.45 µM after a single dose of 50 mg.  
Distribution 
Significant inhibition of PARP levels in both tumor tissue and peripheral blood mononuclear cells 
was observed 3–6 hours after administration 
Metabolism and Excretion  
Veliparib is excreted previously in the urine; however, in a lower percentage (nearly 13%) 
Veliparib undergoes hepatic metabolism by the activity of cytochrome CYP2D6. 
6.3. Clinical activity 
In 2014 Puhalla et al. presented the results of a phase I trial aimed at assessing maximum tolerated 
dose, dose-limiting toxicities, pharmacokinetic and pharmacodynamic properties, and preliminary 
efficacy of Veliparib. Eighty-eight patients, mainly affected by ovarian or breast cancer, were 
enrolled; 60 were BRCA positive and 28 BRCA wild type. The recommended phase 2 dose was 
400 mg BID. The most common toxicities reported were nausea, fatigue, and lymphopenia. The 
half-life was established at 5.2 hours. BRCA mutated patients had an ORR of 23% and a clinical 
benefit rate (CBR; CR + PR + stable disease) of 58% across all dose levels. Among BRCA-wild 
type patients the ORR was 4% with a CBR of 38%. Coleman et al. evaluated the activity of 
Veliparib in a phase II trial in 52 BRCA mutated patients with persistent or recurrent ovarian 
cancer. Sixty percent of patients was platinum resistant. Veliparib was administered at 400 mg 
orally twice a day. No drug related deaths were reported. The most common toxicities observed 
were mielotoxicity and gastrointestinal toxicity. Authors reported a median PFS of 8.11 months 
(ranging from 0.43 to 19.55 months) and a median OS of 19.7 months (ranging from 2.3 to 19.7 
months) [104]. 
Recently, the results of a phase I/II trial have been published exploring the role of Veliparib 
monotherapy in patients with germline BRCA mutations platinum sensitive or resistant ovarian 
cancer. Sixteen patients were enrolled in the phase I study, and 32 in the second part of the study. 
The maximum tolerated dose was established at 300 mg twice daily. Median PFS and OS for the 
intention to treat population were respectively 5.6 and 13.7 months. The most common toxicities 
observed were fatigue, nausea and vomiting [105]. In another phase I study Nishio et al evaluated 
the safety, tolerability, pharmacokinetics and efficacy of Veliparib (100 or 150 twice a day) in 
association with Carboplatin and weekly Paclitaxel in 9 Japanese patients with newly diagnosed 
EOC. The most frequent toxicities were neutropenia, alopecia, neurotoxicity, anemia and nausea. 
Authors reported an ORR of 100% in the 5 patients evaluated (the other 4 had no measurable 
lesions). After this study the dose of Veliparib in association with Carboplatin and Paclitaxel was 
established at 150 mg twice a day [106]. 
The safety of this PARP inhibitor was also assessed in association with chemotherapy (PLD, 
Carboplatin and Bevacizumab) in a phase I trial enrolling patients with platinum sensitive ovarian 
cancer. DLTs reported in the dose escalation part included grade 4 thrombocytopenia and prolonged 
neutropenia. With the addiction of bevacizumab, a DLT was observed in 9 out of 12 patients and 
these included grade 4 thrombocytopenia, prolonged neutropenia, hypertension and sepsis. The 
maximum tolerated dose of Veliparib in association with carboplatin was established at 80 mg twice 
a day [107]. Kummar et al conducted a phase II study comparing low dose Cyclophosphamide 
alone or in association with Veliparib in patients with ovarian cancer. Seventy two patients were 
enrolled; no differences were reported for the two arms of treatment in terms of response rate [108]. 
In a phase I trial Reiss et al. evaluated the activity of Veliparib combined with low-dose 
fractionated whole abdominal radiation therapy in 32 patients with carcinomatosis due to advanced 
solid tumors. Eighteen patients were affected by EOC, 5 of them were BRCA mutations carriers. 
One objective response was observed, and stable disease was reported in 33% of patients. Patients 
with BRCA mutated EOC had a PFS of  4.47 months compared to PFS 3.58 months in the non-
BRCA carriers and an OS of 10.15 months compared to 7.89 months in non-BRCA carriers. 
Patients whit platinum-sensitive disease had a PFS of 7.92 months compared to 3.58 months in 
platinum-resistant EOC. The most frequently observed toxicity was myelosuppression [109]. 
6.4. Current strategies of development  
As discussed above, Veliparib alone has no anti-proliferative effect. However, there are several 
preclinical and clinical evidences of its activity as sensitizing agents for DNA-damaging treatments, 
such as chemotherapy and radiotherapy. As previously reported for Talazoparib, evidences 
supporting the use of Veliparib in the treatment of EOC are fewer compared to those for other 
PARP inhibitors, however several studies are ongoing, both with Veliparib as a single agent and in 
association with chemotherapy, including a phase III trial evaluating Veliparib as first line treatment 
in association with carboplatin and paclitaxel (Table 5). This randomized study includes three 
treatment arms: one with chemotherapy only, the second with chemotherapy followed by Veliparib 
in maintenance and the third with Veliparib associated with chemotherapy followed by Veliparib as 
a maintenance. Considering as primary outcome PFS, an enrolment of 1100 patients is estimated. 
There is also a phase II trial evaluating Veliparib as a single agent for the treatment of relapsed 
EOC (Table 5). Fifty-one patients are expected to be enrolled in this trial, patients with both 
platinum sensitive and platinum resistant disease are eligible but they must have a germline 
BRCA1/2 mutation.  
 
7. CURRENT AND FUTURE DEVELOPMENTS 
The development of PARPis is certainly the most important breakthrough in the treatment of 
ovarian cancer. Both FDA and EMA have already changed clinical practice after Olaparib and 
Niraparib approvals, but several questions regarding their use, strongly connected each other, still 
need an answer. 
1) Which is the optimal clinical setting? 
2) How can we choose among different PARPis? 
3) How can we better identify HRD patients? 
4) How much do we know about resistance to PARPis? 
5) Is it better to use PARPis alone or in association with other agents? 
1) Even thought the activity of PARPis as maintenance therapy has been demonstrated [25] [27] 
[44] ongoing trials are seeking to clarify the ideal time for these agents to be used in the course of 
ovarian cancer. Results from SOLO-1, ARIEL-4, PRIMA and QUADRA trials will help to answer 
this question (for the details see Table 1, 2 and 3). The first three trials aim to demonstrate that an 
early maintenance with PARPis after the frontline treatment could improve the outcome, while 
QUADRA trial is investigating chemotherapy free-regimen in heavily pretreated patients. Indeed, 
even if Olaparib activity has already been investigated in the above mentioned setting by Kaufman 
et al. [80], only FDA has recognized this indication. Moreover, as reported above, during the poster 
session of ESMO 2017 Congress, Olaparib superiority in SOLO-2 study is reported also in heavily 
pre-treated patients, with no difference of efficacy regarding number of prior lines of platinum-
based therapy received [78].
 
Further data, regardless the BRCA status, are looked-for in Europe, in 
order to potentially extend the use of PARPis, first of all Niraparib, in poor setting as platinum 
resistant disease. Moreover Olaparib is currently under investigation in the neoadjuvant setting in 
the NEO trial. 
 
2) At first relapse, BRCA mutated platinum sensitive recurrence ovarian cancer should go for 
secondary cytoreductive surgery, if a complete resection is expected [110]. If patients are not 
eligible for surgery, they should receive a platinum doublet followed by maintenance therapy, either 
with Bevacizumab, or with any PARPis, in case of CR or PR. However the difference in terms of 
PFS is strongly in favor of PARPis. On the contrary, in BRCA WT, PFS results from Bevacizumab 
and Niraparib (the only PARPi for relapsed BRCA WT patients) are similar, and therefore, the 
choice should be based on toxicities and disease characteristics. For example Bevacizumab seems 
more active, in patients with bulky disease, ascites and high Ca125 [111], but it may lead to 
hemorrhage and thrombosis more frequently than Niraparib.  Beyond their activity, each PARPi 
shows different toxicities that can drive clinical choices, particularly in a maintenance setting.  
Nausea and fatigue were the most common side effects, reported in about 50% of patients with 10% 
of G3 or G4 regardless of the type of PARPi [112]. Instead, 3% of patients treated with Olaparib 
reported G3-G4 abdominal pain, while 8% of patients treated with Niraparib developed severe 
hypertension [113].  The percentage of hematologic adverse events varied depending on which 
PARPis were used.  Indeed, while anemia is common in patients treated with Olaparib, Niraparib 
and Rucaparib, neutropenia  and thrombocytopenia are typical side effect of Niraparib (with rate of 
20% and 33% respectively), while Rucaparib is characterized by 10% of asymptomatic increase of 
AST and ALT that normalizes over time  [25] [27] [44]. Niraparib required a dose reduction in 66% 
of patients, while Olaparib in 54% and Rucaparib in 25% of patients nevertheless adverse events 
apparently do not affect quality of life neither in SOLO 2 nor in NOVA trial [114].  Thanks to these 
data, we can actually choose the best PARPi for each patient, considering residual toxicities, disease 
burden and BRCA status. Beside acute toxicities, potential long term toxicities are not clear and 
need careful surveillance. Preclinical model suggests a role of PARP-1 in cardiovascular diseases 
and long-term memory formation [112]. but, above all, an increased risk of MDS /AML was 
reported in patients treated with PARPis. It could be related to the high genomic instability of HRD 
patients (above all BRCA mutated patients) for whom further drugs induce DNA damage could 
raise this risk [112]. Currently, only few data are available on long-term exposure to Olaparib, that 
reported no warning on long-term toxicities [76], but further information, especially on Rucaparib 
and Niraparib, is needed. Moreover, we have no long term benefit predictors to PARPis, although 
an observational and sample collection study (A Study of Long-Term Responders on Olaparib, 
OLALA NCT02489058) is trying to identify them. 
 
3) Even though germline BRCA mutations are the best predictors of PARPis activity in EOC, their 
efficacy has been observed also in patients without this alteration. Niraparib and Rucaparib have 
proved their activity also in HRD positive [27] [44], but different test to examine HRD status were 
used, as summarized in the introduction. While testing for BRCA mutations have already been 
incorporated into everyday clinical practice, a well recognized test to identify BRCAness phenotype 
due to a homologous recombination impairment does not exist yet [115]. Numerous patents have 
been registered regarding new methods trying to determinate HRD status (WO 2016138574 
A1)[116], DNA sequences defects (WO 2017008912 A1)[117] or LOH (9388472)[118]. 
In the near future, the systematic evaluation of RAD51, γH2AX and Fanconi family of genes foci 
together with genomic instability might help to identify patient populations who can be classified as 
responders or non-responders to PARPis (for discussion of resistance mechanism see point 4 
below)[119]. Early data in breast cancer have demonstrated a correlation between cytoplasmic 
PARP expression, detected by immunohistochemistry, a procedure sustainable and reproducible 
also in peripheral hospital, and high sensitivity to treatment
 
[120]. Identification of responders is 
useful to optimize cost-benefit rate. Waiting for the genome profiling, actually the only parameters 
significantly associated with PARPis response, except BRCA status, is PFI, firstly identified by 
Fong in 2010 [69]
 
and confirmed in a Cochrane’s review including nearly 600 patients [121]. 
4) It is well known that even if a patient is BRCA mutant, after a long-term exposure to PARPis, 
develops drug resistance through different mechanisms [122] . The first mechanism studied has 
been the recovery of HRR ability, through secondary mutations restoring BRCA activity, as 
demonstrated by Norquist in a group of 46 recurred EOC. This retrospective analysis showed 
mutations were higher in platinum-resistant patients than in the sensitive ones (46% versus 5%, 
p=0.003) [123]. Dhillon proposed the restoration of BRCA activity begins from BRCA-deficient 
and chemosensitive cells as a consequence of numerous mutations induced by platinum agents. This 
initial restored clone will expand during drug exposure-related selective pressure [124]. A recent 
patent by Yen et al. (US20170035737)[125] proposed a new method by administering COH29 and 
a DNA-damaging agent in a combined synergistic amount. In ARIEL 2 trial PARPis resistance 
seems to be related with secondary mutation of RAD51, one of the gene causing HRD when 
defective. If secondary mutations occur in RAD51C and RAD51D and their activity is recovered 
PARPis resistance arises [126]. Rottenberg and colleagues demonstrated in an in vivo model a 
possible resistance mechanism due to an increased expression of P-Glycoprotein (multi-drug 
resistance protein), a drug efflux pump responsible of a decrease intracellular drug concentration 
[127]. In 2015 Patch performed whole genome sequencing of nearly 100 ovarian cancers and 
reported various other acquired resistance mechanisms such as loss of BRCA1 promoter 
methylation and ABCB1 rearrangement, but their clinical impact are already unknown [128]. 
5) As already described several PARPis associations with molecular-targeted agents, standard 
cytotoxic agents and/or immunotherapy are currently under investigation and in some cases have 
already moved to the clinical trial phase (for complete list of ongoing trials see the above tables). 
While Olaparib and Niraparib have been approved as single-agents maintenance therapy, Veliparib 
seems to be the best candidate for chemotherapy-associations due to its toxicity profile. Several 
patents have recently been published exploring PARPIs combinationations with chemotherapy, 
immune-agents, TKIs or small nucleic acid molecule (e.i patents n. WO/2017/029517A1, 
US20170035737, US20170049767, WO/2017/151554A1, US20170100368, WO 2016209935 A1, 
US20170049767, 9707302, WO/2017/151554A1, WO/2017/013237A1, WO/2017/029517A1)[125, 129-
131]. Interestingly, Blanchette et al. registered the combination between PARPI, a topoisomerase-1 
inhibition and irinotecan (WO/2017/031442A1)[132]; the topoisomerase-1 inhibitor can be 
delivered as a liposomal formulation resulting in an increased efficacy of the PARP inhibitor and 
reduced toxicity of the irinotecan. 
Moreover, a phase I study of Veliparib + whole abdomen radiotherapy has already shown efficacy 
with a 33% rate of stable disease [109] suggesting its potential role also as chemo-sensitizer. On the 
other hand, no definitive data sustain a potential role of RT in increasing systemic PARPis response 
(the well-known abscopal effect) [133] [134]. A robust rationale exists instead on the association of 
PARPis with immunotherapy. BRCA mutant patients show a higher mutational load and number of 
neoantigens than BRCA WT, which reflects in an increased recruitment of tumor infiltrating 
lymphocytes (TILs) and potential response to checkpoints inhibitors[135] [136] [137]. In this field, 
Lambrechts et al. registered a patent (WO 2013153130 A1) [138]to detect mismatch repair (MMR) 
deficient tumors and exploring the synergism between PARPIs and MMR. 
There is also strong pre-clinical evidence that support combination with anti-angiogenic agents. In 
fact the inhibition of VEGF induces chronic hypoxia leading to down-regulation of DNA repair 
mechanisms and creating an artificial HRD status which increase sensitivity to PARPis [84] [139]. 
AVANOVA, OCTOVA and CONCERTO are three examples of active trials exploring this setting.  
For an exhaustive update on patents exploring PARPIs in ovarian cancer see Table 6. 
Finally, a good opportunity to study new drugs and combinations as soon as they are developed is 
to create common bio-banks of tumor tissues as established in phase II ENGOT (NCT03267589) a 
cooperative innovative trial. 
 
8. CONCLUSION 
PARP inhibition has already proved to be an outstanding strategy for improving PFS in ovarian 
cancer, although a longer follow-up is needed to assess also OS benefit.  The development  of new 
combinations  through clinical trials and new patents will provide  a better understanding of 
PARPIs mechanisms of action and hopefully reflects in better clinical benefit for patients. 
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Table 1. Ongoing clinical trials involving Olaparib in EOC.  
 
 Setting Line of therapy Phase Status Trial identifier 
Olaparib Newly diagnosed 
BRCAm 
1L 3 Not yet recruiting NCT01844986 
Olaparib Neoadjuvant 1L 2 Recruiting NCT02489006 
Olaparib+Bevacizum
ab 
gBRCAm manteinance 1L 3 Recruiting NCT02477644 
Olaparib versus 
single agent 
chemotherapy 
Platinum-sensitive 
gBRCAm 
≥3 3 Recruiting NCT02282020 
Olaparib versus 
chemotherapy 
Platinum-sensitive and 
resistant 
regardless BRCA 
status 
≥2 2 Recruiting NCT02822157 
Olaparib+Cediranib Relapsed after Olaparib 
treatment 
≥2 2 Not yet recruiting NCT02340611 
Olaparib  Platinum-sensitive 
HRD positive 
≥2 2 Recruiting NCT02983799 
Olaparib EOC pretreated with 
Olaparib 
responding to 
platinum 
compound 
≥2 3 Recruiting NCT03106987 
Olaparib+Cediranib Platinum-sensitive and 
resistant relapsed 
after PARPi 
≥2 2 Recruiting NCT02681237 
Olaparib+Cediranib 
after chemotherapy 
Platinum-sensitive 
relapsed BRCAm 
pretreated with 
Olaparib 
≥2 1 Recruiting NCT02855697 
Olaparib+Cediranib Platinum-sensitive ≥2 3 Recruiting NCT02446600 
BRCAm 
Olaparib+Cediranib Platinum resistant 
BRCA WT  
≥3 2 Recruiting NCT02889900 
Olaparib+Cediranib 
versus Paclitaxel 
Platinum 
resistant/refractor
y 
≥2 2 Recruiting NCT03314740 
Olaparib±Cediranib 
versus Paclitaxel 
Platinum resistant 
BRCAm 
≥2 2 Recruiting NCT03117933 
Olaparib±Cediranib Maintenance after 
platinum response 
2 3 Not yet Recruiting NCT03278717 
Olaparib and/or 
cediranib+anti-PD1 
Platinum-sensitive or 
resistant 
≥3 1/2 Recruiting NCT02484404 
Olaparib+tremelimu
mab 
Platinum-sensitive or 
resistant BRCAm 
≥2 1/2 Recruiting NCT02571725 
Olaparib+Tremelim
umab+Durvalumab 
Platinum-sensitive or 
resistant BRCAm 
≤3 1/2 Recruiting NCT02953457 
Olaparib+PLD Platinum resistant  ≥2 2 Not yet recruiting NCT03161132 
Olaparib+PM01183 Platinum resistant ≥2 1/2 Recruiting NCT02684318 
Olaparib Maintenance 
BRCAm/HRD+ 
2 4 Recruiting NCT02476968 
Olaparib+Onalespib Platinum resistant ≥3 1 Recruiting NCT02898207 
Olaparib+AZD1775 Platinum resistant ≥3 1b Recruiting NCT02511975 
      
 
  
Table 2. Ongoing clinical trials involving Niraparib in EOC 
 
Combination Setting Line of therapy Phase Status Trial identifier 
Niraparib Platinum-sensitive 1L  3 recruiting NCT02655016 
Niraparib Platinum-resistant >3L 2 recruiting NCT02354586 
Niraparib + Bevacizumab Platinum-sensitive >1L 2 recruiting NCT02354131 
Niraparib + Bevacizumab Platinum-sensitive 1L maintenance 2 recruiting NCT03326193 
Niraparib + 
Pembrolizumab 
Platinum-resistant >2L 1-2 recruiting NCT02657889 
Niraparib + Everolimus Platinum-sensitive 
and resistant 
>1L 1 not yet 
recruiting 
NCT03154281 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3 Ongoing clinical trials involving Rucaparib in EOC. 
 
Combination Setting Line of 
therapy 
Phase Status Trial 
identifier 
Rucaparib Platinum sensitive  >1 2 Ongoing not 
recruiting 
NCT01891344 
Rucaparib + 
Atetolizumab 
Gynaecological 
neoplasms/Breast 
cancer 
>1 1 Recruiting NCT03101280 
Rucaparib vs 
chemotherapy 
Platinum 
sensitive/resistant  
≥3 3 Recruiting NCT02855944 
Rucaparib Ovarian cancer/other 
BRCA mutated 
tumors 
≤4 1/2 Ongoing not 
recruiting 
NCT01482715 
Table 4. Ongoing clinical trials involving Talazoparib in EOC. 
 
Combination Setting Line of 
therapy 
Phase Status Trial identifier 
Talazoparib Neoadjuvant 1 1 Ongoing not 
recruiting 
NCT02316834 
Talazoparib 
+ avelumab 
Platinum sensitive 
EOC/other tumors 
≥1 1/2 Recruiting NCT03330405 
Talazoparib Platinum sensitive 
or platinum naive 
EOC/other tumors  
≥1 1 Recruiting NCT01989546 
Talazoparib  Progression after 
another PARPis  
≥1 2 Completed  
Talazoparib EOC/other tumors any 2 Ongoing not 
recruiting 
NCT02286687 
 
 
 
 
 
 
 
 
 
  
Table 5. Ongoing clinical trials involving Veliparib in EOC 
 
Combination Setting Line of 
therapy 
Phase Status Trial 
identifier 
Veliparib + 
topotecan 
Platinum 
resistant/partially 
resistant EOC 
>1 1/2 Completed NCT01690598 
Veliparib + 
topotecan 
Solid 
tumors/relapsed 
EOC 
<4 1/2 Recruiting NCT01012817 
Veliparib+ 
Carboplatin 
+ Paclitaxel 
Newly 
diagnosed EOC 
1 3 Ongoing not 
recruiting 
NCT02470585 
Veliparib Recurrent EOC >1 2 Ongoing not 
ecruiting 
NCT01540565 
Veliparib + 
Fluxuridine 
 >5 1 Recruiting NCT01749397 
Veliparib + 
PLD 
Recurent 
ovarian/breast 
cancer 
<2 pl based 1 Ongoing not 
recruiting 
NCT01145430 
Veliparib+ 
Carboplatin 
+ Paclitaxel + 
Bevacizumab 
Newly 
diagnosed EOC 
1 1 Ongoing not 
recruiting 
NCT00989651 
 
  
Table 6. Recent patents exploring PARPIs in ovarian cancer. 
 
Patent ID Patent Title Short Description Date of 
registration 
Reference 
number 
WO 2013153130 A1 Novel markers for detecting microsatellite 
instability in cancer and determining synthetic 
lethality with inhibition of the DNA base 
excision repair pathway 
New markers to detect Mismatch Repair 
(MMR) deficient tumors. Innovative treatment 
for MMR-deficient tumors based on the 
synthetic lethal interaction between MMR and 
PARP. 
10 Apr 2013 [138] 
WO/2016/018089A1 Novel biomarker for predicting sensitivity to 
parp Inhibitor, and use thereof 
A novel biomarker to predict response to 
PARPis 
9 Aug 2013 [140] 
US20150290185 
(EP2918292A1) 
Polymeric Compound Having Camptothecin 
Compound And Anti-Cancer Effect Enhancer 
Bound Thereto, And Use of Same 
A polymeric camptothecin compound + a 
PARP inhibitor 
31 Oct 2013 [141] 
US20160138114 
(WO/2014/205105A1) 
Biomarkers of Response to Inhibition of Poly-
ADP Ribose Polymerase (PARP) in Cancer 
Methods of identifying PARPis sensitive 
tumors 
18 Jun 2014 [142] 
9388472  Methods and materials for assessing loss of 
heterozygosity 
Methods and materials used in assaying LOH 
signature in tumor cells  
18 Jun 2014 [118] 
JP2017504623A 
(WO/2015/108986A1) 
Use of PARP inhibitor for treating the patient 
of a breast cancer or an ovarian cancer who 
shows loss of heterozygosis 
Use of PARPis in subject with LOH     14 Jan 2015 [143] 
US20170100368  
(WO 2015184145 A1) 
Use of eribulin and poly (adp ribose) 
polymerase (parp) inhibitors as combination 
therapy for the treatment of cancer 
Eribulin mesylate + PARP inhibithors (e.g., 
E7449) +/- platinum based therapy 
28 May 2015 [144] 
US20150344968 Methods for determining PARP inhibitor and 
platinum resistance in cancer therapy 
BRCA1 exon excision variant sequencing 01 Jun 2015 [145] 
WO 2016138574 A1 Homologous recombination factors Factors that act on homologous recombination, 
method to modulate it. 
1 Mar 2016 [116] 
WO 2016209935 A1 Platinum compounds, compositions, and uses 
thereof 
Platinum compounds having at least one 
reacting group (e.g.  that recognize a selected 
target cell population) 
22 Jun 2016 [146] 
9707302 
(US20170274093) 
Combining anti-HLA-DR or anti-Trop-2 
antibodies with microtubule inhibitors, PARP 
inhibitors, bruton kinase inhibitors or 
phosphoinositide 3-kinase inhibitors 
significantly improves therapeutic outcome in 
PARP inhibitors + adoptive cell therapy, 
bruton kinase inhibitors or PI3K inhibitors 
23 Jun 2016 [147] 
cancer 
WO 2017008912 A1 Method for determining a mutation in genomic 
dna, use of the method and kit for carrying out 
said method 
A mutation analysis is carried out using 
genomic DNA 
15 Jul 2016 [117] 
WO/2017/013237A1 Use of a combination of dbait molecule and 
PARP inhibitors to treat cancer 
PARP inhibitor + nucleic acid molecule 22 Jul 2016 [148] 
WO/2017/031442A1 Combination therapy using liposomal 
irinotecan and a PARP inhibitor for cancer 
treatment 
Irinotecan liposomal formulation (MM-398) 
and Veliparib 
19 Aug 2016 [132] 
WO/2017/029517A1 Compositions comprising phosphoinositide 3-
kinase inhibitors and a second antiproliferative 
agent 
A composition of phosphoinositide 3-kinase 
inhibitors and a second agent (e.g. a PARPi) 
19 Aug 2016 [149] 
US20170035737 Treatment of BRCA1-defective cancer or 
resistant cancers 
COH29 ((N-(4-(3,4-dihydroxyphenyl)-5-
phenylthiazol-2-yl)-3,4-dihydroxybenzamide)) 
9 Feb 2017 [125] 
US20170049767 Combination therapy for cancer treatment Topoisomerase-1 inhibitor + PARPis 23 Feb 2017 [130] 
WO/2017/151554A1 Combination therapy for treatment of ovarian 
cancer 
Ganetespib + a DNA- damaging or repair-
inhibiting agent 
28 Feb 2017 [131] 
 
